Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 double-blind, placebo-controlled study of ART-123 with FOLFOX plus bevacizumab in metastatic colorectal cancer
jRCT2051210165Phase 1Suspended
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in metastatic colon cancer (mCRC) comparing ART-123 arm with Placebo arm (2 arms). Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started Mar 2022; status: suspended.
02
Drugs
thrombomodulin alfa
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2051210165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210165.